Akebia Q2 Revenue Falls on Auryxia Decline, Vafseo Growth Surges 60%
AKBA sits 29% above its 52-week low of $0.823.
Summary
Akebia's Q2 revenue dropped due to generic erosion of Auryxia, but Vafseo revenue jumped 60% with 41% more patients on therapy. The net loss of $8.91M ($0.03/share) beat consensus by a wide margin. Management expects Auryxia to keep declining in 2026 from pricing pressure, while Vafseo's momentum and a two-year cash runway provide a bridge to the ebribafusp Phase 2 data readout in 2027. This follows the June VOICE trial stop for Vafseo on superior safety, reinforcing the drug's commercial trajectory. The beat and Vafseo growth offset the Auryxia headwind, but the negative revenue trend and generic threat keep sentiment cautious.
At the time of this announcement, AKBA was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $346.1M. The 52-week trading range was $0.82 to $3.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.